Scribd Logo
Upload

Welcome to Scribd!

  • 25 views

    Survival Outcome of Combined GnRHagonist and Tamoxi

    Uploaded by

    Clau
    1) The study compared adjuvant treatment with a GnRH agonist (goserelin) plus tamoxifen (GnRH-TAM) to standard chemotherapy of Adriamycin and Cyclophosphamide (AC) plus tamoxifen (AC-TAM) in premenopausal patients with hormone receptor positive, node-negative breast cancer. 2) There was no significant difference in disease-free survival rates between the two treatment groups after a median follow up of 67 months. The 5-year disease-free survival rate was 96.9% for both groups. 3) No adverse effects were reported in patients receiving GnRH-TAM, and compliance was good. The study concludes that

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Survival Outcome of Combined GnRHagonist and Tamoxi

    Uploaded by

    Clau
    25 views1 page
    1) The study compared adjuvant treatment with a GnRH agonist (goserelin) plus tamoxifen (GnRH-TAM) to standard chemotherapy of Adriamycin and Cyclophosphamide (AC) plus tamoxifen (AC-TAM) in premenopausal patients with hormone receptor positive, node-negative breast cancer. 2) There was no significant difference in disease-free survival rates between the two treatment groups after a median follow up of 67 months. The 5-year disease-free survival rate was 96.9% for both groups. 3) No adverse effects were reported in patients receiving GnRH-TAM, and compliance was good. The study concludes that

    Original Description:

    Survival GnRH

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    1) The study compared adjuvant treatment with a GnRH agonist (goserelin) plus tamoxifen (GnRH-TAM) to standard chemotherapy of Adriamycin and Cyclophosphamide (AC) plus tamoxifen (AC-TAM) in premenopausal patients with hormone receptor positive, node-negative breast cancer. 2) There was no significant difference in disease-free survival rates between the two treatment groups after a median follow up of 67 months. The 5-year disease-free survival rate was 96.9% for both groups. 3) No adverse effects were reported in patients receiving GnRH-TAM, and compliance was good. The study concludes that

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    25 views1 page

    Survival Outcome of Combined GnRHagonist and Tamoxi

    Uploaded by

    Clau
    1) The study compared adjuvant treatment with a GnRH agonist (goserelin) plus tamoxifen (GnRH-TAM) to standard chemotherapy of Adriamycin and Cyclophosphamide (AC) plus tamoxifen (AC-TAM) in premenopausal patients with hormone receptor positive, node-negative breast cancer. 2) There was no significant difference in disease-free survival rates between the two treatment groups after a median follow up of 67 months. The 5-year disease-free survival rate was 96.9% for both groups. 3) No adverse effects were reported in patients receiving GnRH-TAM, and compliance was good. The study concludes that

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 1

    Survival outcome of combined GnRH agonist and

    tamoxifen is comparable to that of sequential adriamycin


    and cyclophosphamide chemotherapy plus tamoxifen in
    premenopausal early breast cancer patients
    Thitikon Krisorakun MD , Doonyapat Sa-nguanraksa MD, PhD, Pornchai O-charoenrat MD, PhD *

    Division of Head Neck and Breast Surgery, Department of Surgery, Siriraj Hospital, Mahidol University, Bangkok, Thailand 10700

    Background There were no significant difference in the most There was no mortality in either group.
    of demographic parameters, except types of There was no significant difference in DFS
    Ovarian function suppression (OFS) has surgery and radiation administration between the two groups (GnRH-TAM vs AC-
    been shown to improve the outcome of TAM: 96.9% vs 96.9%, HR = 0.637,
    high-risk premenopausal patients when (95%CI=0.080-5.081), p=0.671).
    combined with tamoxifen, but this benefit No adverse effect was occurred and good
    was not established in a low-risk group compliance was observed in all patients who
    Patients administered with a GnRH agonist received GnRH-TAM.
    alone demonstrated better quality of life
    compared to those who treated with
    adjuvant chemotherapy
    Only few studies have illustrated the GnRH
    agonists as substitutes for chemotherapy
    in hormone-responsive breast cancer
    patients

    Aim
    To compare the effect of two adjuvant
    treatment regimens, the GnRH agonist
    plus tamoxifen (GnRH-TAM) versus
    standard chemotherapy with Adriamycin
    and Cyclophosphamide (AC) plus
    tamoxifen (AC-TAM), on overall survival
    (OS) and disease-free survival (DFS) in
    premenopausal patients having hormonal
    receptor positive, node-negative, early Figure 1: Kaplan-Meier curve of disease free survival of
    stage breast cancer. GnRH-TAM vs AC-TAM

    Methods Conclusion
    Retrospective non-inferior trial Table 1: Baseline characteristics of patients, tumors and
    In premenopausal women with
    The patients were recruited from the treatments hormone-receptor positive, node-
    Division of Head Neck and Breast Surgery, negative early breast cancer, adjuvant
    Department of Surgery, Siriraj Hospital, treatment with GnRH-TAM represents a
    Mahidol University, Thailand between 2005- valid option with similar survival
    2015.
    Inclusion criterias:
    outcomes as those who were treated
    Premenopausal breast cancer with AC-TAM.
    patients
    Tumor size < 3 cm References
    Node-negative 1. Pujol P, et al. Changing estrogen and progesterone
    Hormonal receptor positive receptor patterns in breast cancer carcinoma during the
    No neoadjuvant treatment menstrual cycle and menopause. Cancer 1998; 83:698705.
    2. Klijn JG, et al. Combined tamoxifen and luteinising
    No distant metastasis hormone releasing hormone(LHRH) agonist versus LHRH
    Patients either received GnRH-TAM or AC- agonist alone in premenopausal advanced breast cancer: a
    TAM. In the GnRH-TAM group, the patients meta-analysis of four randomised trials. J Clin Oncol
    2001;19:34353.
    received subcutaneous injection of 10.8 mg
    3. Baum M, et al. Adjuvant Zoladex in premenopausal
    of Goserelin every 3 months for 2-3 years patients with early breast cancer: results from the ZIPP trial.
    and TAM (20 mg per day) for 5 years. Breast 2001;10(Supp1): S32-3.
    In the AC-TAM group, AC was administered 4. Schmid P, et al. Leuprorelin acetate every-3-months depot
    versus cyclophosphamide,methotrexate, and fluorouracil as
    every 3 weeks for 4 cycles followed by TAM adjuvant treatment in premenopausal patients with node-
    (20 mg per day) for 5 years. positive breast cancer: The TABLE Study. J Clinl Oncol
    2007;25:250915.
    5. Kaufmann Ma, et al. Survival analyses from the ZEBRA
    Results study. goserelin (Zoladex) versus CMF in premenopausal
    women with node-positive breast cancer. Eur J Cancer
    40 patients received GnRH-TAM and 217 2003;39:17117
    patients received AC-TAM.
    Median follow up time was 67 months Table 2: Factors affecting recurrence according to GnRH-TAM,
    *Corresponding author:
    (range 8-176 months). AC-TAM groups univariate analysis [email protected]

    You might also like